The Role of Diabetes Mellitus as an Effect Modifier of the Association Between Smoking Cessation and Its Clinical Prognoses: An Observational Cohort Study
Restricted accessResearch articleFirst published online January, 2021
The Role of Diabetes Mellitus as an Effect Modifier of the Association Between Smoking Cessation and Its Clinical Prognoses: An Observational Cohort Study
The smoker’s paradox refers to an increased risk of adverse clinical outcomes after smoking cessation in patients with coronary artery disease. The mechanisms involved are controversial. The present study evaluated the effect of delay in smoking cessation on clinical outcomes among patients after percutaneous coronary intervention (PCI) stratified by diabetes mellitus (DM). Patients included in this study came from an established Fu Wai hospital PCI cohort. Smoking behavior was recorded; clinical end points included all-cause mortality and repeat revascularization. The analyses were based on 8489 smokers who underwent PCI. Patients with and without DM were examined separately. Multivariable model analysis suggested that smoking cessation was associated with significant lower all-cause mortality both for non-DM and DM patients. The smoking paradox was observed for revascularization. However, the increased risk of repeat revascularization correlated with quitting time among non-DM patients only, especially if they stopped smoking late (>90 days) after their index procedure (adjusted hazard ratio, 3.40; 95% CI: 2.45-4.72). In conclusion, smoking cessation is associated with a lower mortality rate for PCI patients. However, the relative benefit on repeated revascularization was only observed among non-DM patients if they quit smoking early.
ZhangYJIqbalJvan KlaverenD, et al.Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol. 2015;65:1107–15.
2.
de BoerSPSerruysPWValstarG, et al.Life-years gained by smoking cessation after percutaneous coronary intervention. Am J Cardiol. 2013;112:1311–4.
3.
ChenTLiWWangYXuBGuoJ. Smoking status on outcomes after percutaneous coronary intervention. Clin Cardiol. 2012;35:570–4.
4.
BanksEJoshyGKordaRJ, et al.Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med. 2019;17:128.
5.
CohenDJDoucetMCutlipDE, et al.Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker’s paradox?Circulation. 2001;104:773–8.
6.
WeiszGCoxDAGarciaE, et al.Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction – the smoker’s paradox revisited. Am Heart J. 2005;150:358–64.
7.
AuneERoislienJMathisenMThelleDSOtterstadJE. The “smoker’s paradox” in patients with acute coronary syndrome: a systematic review. BMC Med. 2011;9:97.
8.
BarbashGIReinerJWhiteHD, et al.Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the “smoker’s paradox” from the GUSTO-I trial, with angiographic insights. Global utilization of streptokinase and tissue-plasminogen activator for occluded coronary arteries. J Am Coll Cardiol. 1995;26:1222–9.
9.
AndrikopoulosGKRichterDJDilaverisPE, et al.In-hospital mortality of habitual cigarette smokers after acute myocardial infarction; the “smoker’s paradox” in a countrywide study. Eur Heart J. 2001;22:776–84.
10.
KatayamaTIwasakiYSakodaNYoshiokaM. The etiology of “smoker’s paradox” in acute myocardial infarction with special emphasis on the association with inflammation. Int Heart J. 2008;49:13–24.
11.
YalcinEde la MonteS. Tobacco nitrosamines as culprits in disease: mechanisms reviewed. J Physiol Biochem. 2016;72:107–20.
12.
ChaitmanBRHardisonRMAdlerD, et al.The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation. 2009;120:2529–40.
13.
FryeRLAugustPBrooksMM, et al.A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–15.
14.
ChristianRGeorgeC. Monte Carlo Statistical Methods (2nd ed). Springer-Verlag; 2004.
15.
van BerkelTFBoersmaHRoos-HesselinkJWErdmanRASimoonsML. Impact of smoking cessation and smoking interventions in patients with coronary heart disease. Eur Heart J. 1999;20:1773–82.
16.
van DomburgRTMeeterKvan BerkelDF, et al.Smoking cessation reduces mortality after coronary artery bypass surgery: a 20-year follow-up study. J Am Coll Cardiol. 2000;36:878–83.
17.
HammalFEzekowitzJANorrisCMWildTCFineganBA. Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. BMC Cardiovasc Disord. 2014;14:133.
18.
CritchleyJACapewellS. Withdrawn: smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2012;2:CD003041.
19.
HasdaiDGarrattKNGrillDELermanAHolmesDJ. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med. 1997;336:755–61.
20.
EpsteinKAViscoliCMSpenceJD, et al.Smoking cessation and outcome after ischemic stroke or TIA. Neurology. 2017;89:1723–1729.
21.
SinghMWilliamsBAGershBJ, et al.Geographical differences in the rates of angiographic restenosis and ischemia-driven target vessel revascularization after percutaneous coronary interventions: results from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. J Am Coll Cardiol. 2006;47:34–9.
22.
GerberYRosenLJGoldbourtUBenyaminiYDroryY. Smoking status and long-term survival after first acute myocardial infarction a population-based cohort study. J Am Coll Cardiol. 2009;54:2382–7.
23.
AndrikopoulosGKChimonasETToutouzasPK. Paradoxical clinical value of another smoker’s paradox. Circulation. 2002;105:e55.
24.
SochorOLennonRJRodriguez-EscuderoJP, et al.Trends and predictors of smoking cessation after percutaneous coronary intervention (from Olmsted County, Minnesota, 1999 to 2010). Am J Cardiol. 2015;115:405–10.
25.
JonerMNakazawaGFinnAV, et al.Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333–42.
26.
PlassCASabdyusheva-LitschauerIBernhartA, et al.Time course of endothelium-dependent and -independent coronary vasomotor response to coronary balloons and stents. comparison of plain and drug-eluting balloons and stents. JACC Cardiovasc Inter. 2012;5:741–51.
27.
BakhruAErlingerTP. Smoking cessation and cardiovascular disease risk factors: results from the third national health and nutrition examination survey. Plos Med. 2005;2:e160.
28.
ObataJENakamuraTKittaY, et al.Treatment of acute myocardial infarction with sirolimus-eluting stents results in chronic endothelial dysfunction in the infarct-related coronary artery. Circ Cardiovasc Inter. 2009;2:384–91.
29.
BenowitzNL. Cigarette smoking and nicotine addiction. Med Clin North Am. 1992;76:415–37.
30.
YunAJBazarKALeePYGerberADanielSM. The smoking gun: many conditions associated with tobacco exposure may be attributable to paradoxical compensatory autonomic responses to nicotine. Med Hypotheses. 2005;64:1073–9.
31.
HabibAKarmaliVPolavarapuR, et al.Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. J Am Coll Cardiol. 2013;61:971–80.
